静脉晶体液用量超过1升是否与创伤患者更差结局相关?
该单中心回顾性研究纳入2018年1月至2019年9月间初始心率≥100次/分或收缩压≤90 mmHg的创伤患者878例,分析入院后3小时内加院前晶体液总量与结局的关联。多因素分析显示,接受>1 L晶体液与院内死亡率(p=0.61)或输注浓缩红细胞量(p=0.29)无显著关联,但与住院时间延长相关(p=0.04);完全不给晶体液与死亡率、输血量或住院时间均无关联。结论提示>1 L晶体液未显示增加死亡或输血风险,但可能延长住院时间,且完全限制晶体液无益。
要点
- 纳入标准为初始心率≥100次/分或收缩压≤90 mmHg的创伤患者,共878例。
- 45.0%的患者在入院后3小时内加院前接受>1 L静脉晶体液。
- 多因素分析:>1 L晶体液与院内死亡率无显著关联(p=0.61),与输注浓缩红细胞量无显著关联(p=0.29)。
- >1 L晶体液与住院时间延长显著相关(p=0.04)。
- 完全不给晶体液与死亡率、输血量或住院时间均无关联,无获益证据。
适用人群与场景
- 单中心创伤登记数据库中初始心率≥100次/分或收缩压≤90 mmHg的创伤患者,分析入院后3小时内加院前静脉晶体液总量。
诊断标准与关键阈值
- 纳入条件:初始心率≥100次/分或收缩压≤90 mmHg。
- 晶体液暴露分组:≤1 L vs >1 L(入院后3小时内加院前总量);另分析完全不给晶体液。
处置流程与药物剂量
- 原文未提及具体复苏流程或药物剂量推荐。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 单中心回顾性研究,2018年1月1日至2019年9月30日纳入878例符合标准的创伤患者。
- 55.0%接受≤1 L静脉晶体液,45.0%接受>1 L。
- 多因素分析:>1 L晶体液与院内死亡率无显著关联(p=0.61),与输注浓缩红细胞量无显著关联(p=0.29),但与住院时间延长显著相关(p=0.04)。
- 完全不给晶体液与死亡率、输注浓缩红细胞量或住院时间均无关联。
证据类型、等级与局限
- 证据类型:单中心回顾性研究,使用创伤登记数据并补充人工病历回顾。
- 局限:单中心、回顾性设计,原文未提及证据等级。
对床旁实践的改变
- 对于初始心率≥100次/分或收缩压≤90 mmHg的创伤患者,接受>1 L晶体液未显示增加院内死亡或输血风险,但可能与住院时间延长相关,临床可据此权衡晶体液用量。
- 完全不给晶体液在该人群中未显示获益,不支持刻意限制晶体液至零。
- 原文未提及适用与不适用人群的进一步区分。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Advanced Trauma Life Support guidelines recommend only 1 L of intravenous (IV) crystalloid before transitioning to blood products. We sought to determine if receiving >1 L of IV crystalloid during the initial resuscitation is associated with worse outcomes. We also sought to determine if receiving no crystalloids is associated with better outcomes.
METHODS: We performed a single center retrospective study using trauma registry data, which was supplemented by manual chart review. We only included patients who had an initial heart rate ≥ 100 beats/min or a systolic blood pressure ≤ 90 mmHg. For each patient, we determined the total amount of IV crystalloid administered in the first 3 h after arrival to the hospital plus prehospital crystalloid. We performed multivariate regression analyses to determine if there is an association between the administration of >1 L of crystalloids or no crystalloids with in-hospital mortality, hospital length of stay (LOS), or packed red blood cells (PRBCs) transfused.
RESULTS: Between January 1, 2018 and September 30, 2019, there were 878 who met criteria for enrollment. Among those, 55.0% received ≤1 L of IV crystalloids, and 45.0% received >1 L. Multivariate analyses showed no significant association between receiving >1 L and mortality (p = 0.61) or PRBCs transfused (p = 0.29), but patients who received >1 L had longer hospital LOS (p = 0.04). We found no association between receiving no crystalloids and mortality, PRBCs transfused, or LOS.
CONCLUSION: On a multivariate analysis of trauma patients, we did not find an association between the administration of >1 L of IV crystalloid and in-hospital mortality or the volume of PRBCs transfused. However, receiving >1 L of crystalloids was associated with a longer hospital LOS. We found no benefit to completely withholding crystalloids.
参考来源
- Zitek T, Ataya R, Farino L, et al. Is the use of greater than 1 L of intravenous crystalloids associated with worse outcomes in trauma patients? Am J Emerg Med. 2020. PMID: 33340875. doi:10.1016/j.ajem.2020.12.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。